Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|06/09/2019||Notice of General Meeting/Proxy Form||Download|
|23/08/2019||Appendix 4E & Annual Report||Download|
|20/08/2019||Change in substantial holding||Download|
|20/08/2019||Information Required under ASX Listing Rule 3.10.5A||Download|
|20/08/2019||Becoming a substantial holder||Download|